SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-19-002500
Filing Date
2019-01-04
Accepted
2019-01-04 16:00:36
Documents
3
Period of Report
2019-01-03
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d682851d8k.htm 8-K 28456
2 EX-99.1 d682851dex991.htm EX-99.1 14246
3 GRAPHIC g682851g33i43.jpg GRAPHIC 5937
  Complete submission text file 0001193125-19-002500.txt   52482
Mailing Address 8000 MARINA BOULEVARD SUITE 300 BRISBANE CA 94005-1884
Business Address 8000 MARINA BOULEVARD SUITE 300 BRISBANE CA 94005-1884 (650) 614-5220
Aimmune Therapeutics, Inc. (Filer) CIK: 0001631650 (see all company filings)

IRS No.: 452748244 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37519 | Film No.: 19509907
SIC: 2834 Pharmaceutical Preparations